Brought to you by 
Lilly and Dicerna enter RNAi collaboration; potential deal value tops $3.7bn
24 Nov 2021
Executive Summary
Eli Lilly & Co. partnered with Dicerna Pharmaceuticals Inc. to discover and develop RNAi therapies for cardio-metabolic diseases, neurodegeneration, and pain.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Final
Deal Type
-
Alliance
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Lilly and Dicerna enter RNAi collaboration; potential deal value tops $3.7bn
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice